Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer (2019)

Peer-Reviewed Study · Zaheed M, Wilcken N, Willson ML, O'Connell DL, Goodwin A (Cochrane Database Syst Rev 2019;2(2):CD012873) · February 18, 2019

Zaheed M et al., 2019-02-18: Cochrane review of whether anthracyclines should precede or follow taxanes in early breast cancer. In the neoadjuvant setting the sequence made no difference to outcomes; in the adjuvant setting no included trial reported survival outcomes at all.

In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice.

Abstract (AUTHORS' CONCLUSIONS)

Zaheed M et al., 2019-02-18: Cochrane review of whether anthracyclines should precede or follow taxanes in early breast cancer. In the neoadjuvant setting the sequence made no difference to outcomes; in the adjuvant setting no included trial reported survival outcomes at all. Funder: internal – NHMRC Clinical Trials Centre, University of Sydney; external – NIHR Cochrane Incentive Awards Scheme 2017 (UK public). Conflicts: all authors 'none known'. Drugs: anthracycline and taxane regimens; makers not named. Comparator: reverse sequence of the same two drug classes. Key limitation: adjuvant evidence base contains no survival data – a direct check on claims that sequencing evidence is settled. PMC6378927. Study type: review.